Blood Preparation Market is expected to reach US$ 64.36 Bn. at a CAGR of 5.7 % during the forecast period 2029. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.To know about the Research Methodology :- Request Free Sample Report The growth is coupled with the factors including increasing aging population, advancement in the technology, and increasing patient awareness level. Increasing blood disorder prevalence and rising emergency surgeries in hospitals also expected to drive the market through the forecast period. Further, increased acceptance of advanced blood testing technologies has accelerated accurate diagnosis of haemato logical disorders. Other factors including growing demand for blood and its component due to the increase in target diseases, accidents, and surgeries is expected to drive the market for blood preparation market through the forecast period. In addition, growing emergency cases in the emergency departments coupled with rising demand for blood transfusion is expected to fuel the Global Blood Preparation Market growth. Organizations such as the National Institutes of Health (NIH) and the Centre for Disease Control (CDC) are taking initiatives for raising awareness levels via programs that aim to prevent thrombosis-associated complications in early stages and thus, drive the Global Blood Preparation Market for blood preparation through the forecast period. North America dominated the market in 2022. The market growth is driven by a high incidence of blood cancer and increasing prevalence of cardiovascular, haematological, and neurological diseases in U.S. and Canada. In addition, increasing patient awareness levels coupled with relatively higher healthcare expenditure levels and sophisticated healthcare infrastructure also expected to drive the Global Blood Preparation Market through 2024. U.S. is expected to lead the market owing to increasing thrombocytosis disorder incidence in the country. Asia-Pacific is expected to have higher growth rate in the forecast period owing to high number of blood-associated disorders, high unmet needs and various initiatives taken by governments od China and India. The growth of healthcare sector across Australia and Japan will also expected to drive the Global Blood Preparation Market. Other factors including presence of untapped opportunities, economic development, and rising initiatives by private and public organizations also expected to drive the market in Asia-Pacific region. Whole blood product segment held the highest market in 2022. The market growth is driven by the factors including increasing demand for whole blood for major surgeries, accidents, and transfusions and associated advantages with whole blood, such as easy availability, low cost, and minimal maintenance. The objective of the report is to present comprehensive Global Blood Preparation Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Blood Preparation Marketket North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Global Blood Preparation Marketket North America for Asia Pacific size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Blood Preparation Marketket North America for Asia Pacific make the report investor’s guide.
Blood Preparation Market Scope: Inquire before buying
Blood Preparation Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 43.66 Bn. Forecast Period 2023 to 2029 CAGR: 5.7% Market Size in 2029: US $ 64.36 Bn. Segments Covered: by Product Whole Blood Red Cells Granulocytes Plasma Plateletso Blood Components Whole Blood Components Packed Red Cells Leukocyte Reduced Red Blood Cells Frozen Plasma Platelet Concentrate by Type Platelet Aggregation Inhibitors Glycoprotein Inhibitors COX Inhibitors ADP Antagonists Phosphodiesterase Inhibitorso Fibrinolytics Tissue Plasminogen Activator (tPA) Streptokinase Urokinaseo Anticoagulants Heparins by Application Thrombocytosis Pulmonary Embolism Renal Impairment Others Blood Preparation Market, by Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Blood Preparation Market Key Players:
1. Celgene Corp 2. AstraZeneca Co. 3. Sanofi Aventis Leo Pharma Inc. 4. Bristol-Myers Squibb Co 5. Baxter Healthcare Corp. 6. Pfizer Inc. 7. Shandong East Chemical Industry Co 8. GlaxoSmithKline PLC 9. Bristol-Myers Squibb Company 10. Merc & Co., Inc. 11. Novartis Pharmaceuticals 12. AbbVie Inc. 13. Johnson & Johnson Pvt. Ltd. 14. Amgen Inc. 15. Teva pharmaceutical Industries Ltd. 16. Takeda Pharmaceutical Co. Ltd. 17. Astellas Pharma Inc 18. Eli Lilly 19. F.Hoffmann-La Roche Ltd. 20. Joh 21. Roche Holding AG 22. Novartis AG 23. Thermo Fisher Scientific Inc. 24. Laboratory Corporation of America HoldingsFrequently Asked questions
1. What is the market size of the Global Blood Preparation Market in 2022? Ans. The market size Global Blood Preparation Market in 2022 was US$ 43.66 Billion. 2. What are the different segments of the Global Blood Preparation Market? Ans. The Global Blood Preparation Market is divided into Product, Application and Type. 3. What is the study period of this market? Ans. The Global Blood Preparation Market will be studied from 2022 to 2029. 4. Which region is expected to hold the highest Global Blood Preparation Market share? Ans. The Asia Pacific dominates the market share in the market. 5. What is the Forecast Period of Global Blood Preparation Market? Ans. The Forecast Period of the market is 2023-2029 in the market.
Chapter 1 Research Methodology 1.1. Research Methodology 1.2. Market definition 1.3. Assumptions and Acronyms Used 1.4. Data Sources 1.4.1. Secondary 1.4.1.1. Paid 1.4.1.2. Unpaid 1.4.2. Primary Chapter 2 Executive Summary 2.1. Global Blood Preparation Market overview 2.1.1. By Product 2.1.2. By Type 2.1.3. By Applications Chapter 3 Global Blood Preparation Market Industry Insights 3.1. Market segmentation and scope of study 3.2. Market Drivers and their impact analysis 3.2.1. Market Drivers 3.2.1.1. Increasing number of patients in emergency departments 3.2.2. Market Restrains 3.2.2.1. Chances of transmission of diseases such as viral hemorrhagic fever, HIV, and Hepatitis B are high during blood transfusion 3.3. Market share analysis 3.3.1. By Product 3.3.2. By Type 3.3.3. By Applications 3.4. Competitive analysis 3.4.1. Key strategic initiatives 3.4.2. Regional presence 3.4.3. Product overview 3.5. Porter’s analysis 3.6. PESTEL analysis Chapter 4 Blood Preparation Market, By Products 4.1. Key segment trends 4.2. Whole Blood 4.2.1. Market size, by region, 2022-2029 4.3. Red Cells 4.3.1. Market size, by region, 2022-2029 4.4. Granulocytes 4.4.1. Market size, by region, 2022-2029 4.5. Plasma 4.5.1. Market size, by region, 2022-2029 4.6. Platelets 4.6.1. Market size, by region, 2022-2029 4.7. Blood Components 4.7.1. Market size, by region, 2022-2029 4.8. Whole Blood Components 4.8.1. Market size, by region, 2022-2029 4.9. Packed Red Cells 4.9.1. Market size, by region, 2022-2029 4.10. Leukocyte Reduced Red Blood Cells 4.10.1. Market size, by region, 2022-2029 4.11. Frozen Plasma 4.11.1. Market size, by region, 2022-2029 4.12. Platelet Concentrate 4.12.1. Market size, by region, 2022-2029 4.13. Blood Derivatives 4.13.1. Market size, by region, 2022-2029 Chapter 5 Blood Preparation Market, By Type 5.1. Key segment trends 5.2. Platelet Aggregation Inhibitors 5.2.1. Market size, by region, 2022-2029 5.3. Glycoprotein Inhibitors 5.3.1. Market size, by region, 2022-2029 5.4. COX Inhibitors 5.4.1. Market size, by region, 2022-2029 5.5. ADP Antagonists 5.5.1. Market size, by region, 2022-2029 5.6. Phosphodiesterase Inhibitors 5.6.1. Market size, by region, 2022-2029 5.7. Fibrinolytics 5.7.1. Market size, by region, 2022-2029 5.8. Tissue Plasminogen Activator (tPA) 5.8.1. Market size, by region, 2022-2029 5.9. Streptokinase 5.9.1. Market size, by region, 2022-2029 5.10. Urokinase 5.10.1. Market size, by region, 2022-2029 5.11. Anticoagulants 5.11.1. Market size, by region, 2022-2029 5.12. Heparins 5.12.1. Market size, by region, 2022-2029 5.13. Unfractionated Heparin 5.13.1. Market size, by region, 2022-2029 5.14. Low Molecular Weight Heparin (LMWH) 5.14.1. Market size, by region, 2022-2029 5.15. Ultra-low Molecular Weight Heparin 5.15.1. Market size, by region, 2022-2029 5.16. Vitamin K Antagonists 5.16.1. Market size, by region, 2022-2029 5.17. Direct Thrombin Inhibitors 5.17.1. Market size, by region, 2022-2029 5.18. Direct Factor Xa Inhibitors 5.18.1. Market size, by region, 2022-2029 Chapter 6 Blood Preparation Market, By Applications 6.1. Key segment trends 6.2. Thrombocytosis 6.2.1. Market size, by region, 2022-2029 6.3. Pulmonary Embolism 6.3.1. Market size, by region, 2022-2029 6.4. Renal Impairment 6.4.1. Market size, by region, 2022-2029 6.5. Hospital grade 6.5.1. Market size, by region, 2022-2029 Chapter 7 Blood Preparation Market, By Region 7.1. Key regional trends 7.2. North America 7.2.1. Market size, by country, 2022-2029 7.2.2. Market size, by type, 2022-2029 7.2.3. Market size, by products, 2022-2029 7.2.4. Market size, by applications, 2022-2029 7.2.5. U.S. 7.2.5.1. Market size, by type, 2022-2029 7.2.5.2. Market size, by products, 2022-2029 7.2.5.3. Market size, by applications, 2022-2029 7.2.6. Canada 7.2.6.1. Market size, by type, 2022-2029 7.2.6.2. Market size, by products, 2022-2029 7.2.6.3. Market size, by applications, 2022-2029 7.3. Europe 7.3.1. Market size, by country, 2022-2029 7.3.2. Market size, by type, 2022-2029 7.3.3. Market size, by products, 2022-2029 7.3.4. Market size, by applications, 2022-2029 7.3.5. Germany 7.3.5.1. Market size, by type, 2022-2029 7.3.5.2. Market size, by products, 2022-2029 7.3.5.3. Market size, by applications, 2022-2029 7.3.6. UK 7.3.6.1. Market size, by type, 2022-2029 7.3.6.2. Market size, by products, 2022-2029 7.3.6.3. Market size, by applications, 2022-2029 7.3.7. France 7.3.7.1. Market size, by type, 2022-2029 7.3.7.2. Market size, by products, 2022-2029 7.3.7.3. Market size, by applications, 2022-2029 7.3.8. Spain 7.3.8.1. Market size, by type, 2022-2029 7.3.8.2. Market size, by products, 2022-2029 7.3.8.3. Market size, by applications, 2022-2029 7.3.9. Italy 7.3.9.1. Market size, by type, 2022-2029 7.3.9.2. Market size, by products, 2022-2029 7.3.9.3. Market size, by applications, 2022-2029 7.4. Asia Pacific 7.4.1. Market size, by country, 2022-2029 7.4.2. Market size, by type, 2022-2029 7.4.3. Market size, by products, 2022-2029 7.4.4. Market size, by applications, 2022-2029 7.4.5. India 7.4.5.1. Market size, by type, 2022-2029 7.4.5.2. Market size, by products, 2022-2029 7.4.5.3. Market size, by applications, 2022-2029 7.4.6. China 7.4.6.1. Market size, by type, 2022-2029 7.4.6.2. Market size, by products, 2022-2029 7.4.6.3. Market size, by applications, 2022-2029 7.4.7. Japan 7.4.7.1. Market size, by type, 2022-2029 7.4.7.2. Market size, by products, 2022-2029 7.4.7.3. Market size, by applications, 2022-2029 7.4.8. Australia 7.4.8.1. Market size, by type, 2022-2029 7.4.8.2. Market size, by products, 2022-2029 7.4.8.3. Market size, by applications, 2022-2029 7.5. Latin America 7.5.1. Market size, by country, 2022-2029 7.5.2. Market size, by type, 2022-2029 7.5.3. Market size, by products, 2022-2029 7.5.4. Market size, by applications, 2022-2029 7.5.5. Argentina 7.5.5.1. Market size, by type, 2022-2029 7.5.5.2. Market size, by products, 2022-2029 7.5.5.3. Market size, by applications, 2022-2029 7.5.6. Brazil 7.5.6.1. Market size, by type, 2022-2029 7.5.6.2. Market size, by products, 2022-2029 7.5.6.3. Market size, by applications, 2022-2029 7.5.7. Mexico 7.5.7.1. Market size, by type, 2022-2029 7.5.7.2. Market size, by products, 2022-2029 7.5.7.3. Market size, by applications, 2022-2029 7.6. Middle East and Africa 7.6.1. Market size, by country, 2022-2029 7.6.2. Market size, by type, 2022-2029 7.6.3. Market size, by products, 2022-2029 7.6.4. Market size, by applications, 2022-2029 7.6.5. South Africa 7.6.5.1. Market size, by type, 2022-2029 7.6.5.2. Market size, by products, 2022-2029 7.6.5.3. Market size, by applications, 2022-2029 7.6.6. Saudi Arabia 7.6.6.1. Market size, by type, 2022-2029 7.6.6.2. Market size, by products, 2022-2029 7.6.6.3. Market size, by applications, 2022-2029 Chapter 8 Consolidations 8.1. Mergers and Acquisitions 8.2. Partnership, Joint Ventures and Strategic Alliances/Sales Agreements 8.3. Patent Analysis 8.4. Key players 8.4.1. Celgene Corp 8.4.1.1. Company overview 8.4.1.2. Key financials 8.4.1.3. Product landscape 8.4.1.4. Strategic initiatives 8.4.1.5. SWOT analysis 8.4.2. AstraZeneca Co. 8.4.2.1. Company overview 8.4.2.2. Key financials 8.4.2.3. Product landscape 8.4.2.4. Strategic initiatives 8.4.2.5. SWOT analysis 8.4.3. Sanofi Aventis Leo Pharma Inc. 8.4.3.1. Company overview 8.4.3.2. Key financials 8.4.3.3. Product landscape 8.4.3.4. Strategic initiatives 8.4.3.5. SWOT analysis 8.4.4. Bristol-Myers Squibb Co 8.4.4.1. Company overview 8.4.4.2. Key financials 8.4.4.3. Product landscape 8.4.4.4. Strategic initiatives 8.4.4.5. SWOT analysis 8.4.5. Baxter Healthcare Corp. 8.4.5.1. Company overview 8.4.5.2. Key financials 8.4.5.3. Product landscape 8.4.5.4. Strategic initiatives 8.4.5.5. SWOT analysis 8.4.6. Pfizer Inc. 8.4.6.1. Company overview 8.4.6.2. Key financials 8.4.6.3. Product landscape 8.4.6.4. Strategic initiatives 8.4.6.5. SWOT analysis 8.4.7. Shandong East Chemical Industry Co 8.4.7.1. Company overview 8.4.7.2. Key financials 8.4.7.3. Product landscape 8.4.7.4. Strategic initiatives 8.4.7.5. SWOT analysis 8.4.8. GlaxoSmithKline PLC 8.4.8.1. Company overview 8.4.8.2. Key financials 8.4.8.3. Product landscape 8.4.8.4. Strategic initiatives 8.4.8.5. SWOT analysis 8.4.9. Leo Pharma 8.4.9.1. Company overview 8.4.9.2. Key financials 8.4.9.3. Product landscape 8.4.9.4. Strategic initiatives 8.4.9.5. SWOT analysis 8.4.10. Bristol-Myers Squibb Company 8.4.10.1. Company overview 8.4.10.2. Key financials 8.4.10.3. Product landscape 8.4.10.4. Strategic initiatives 8.4.10.5. SWOT analysis 8.4.11. Merc & Co., Inc. 8.4.11.1. Company overview 8.4.11.2. Key financials 8.4.11.3. Product landscape 8.4.11.4. Strategic initiatives 8.4.11.5. SWOT analysis 8.4.12. Novartis Pharmaceuticals 8.4.12.1. Company overview 8.4.12.2. Key financials 8.4.12.3. Product landscape 8.4.12.4. Strategic initiatives 8.4.12.5. SWOT analysis 8.4.13. AbbVie Inc. 8.4.13.1. Company overview 8.4.13.2. Key financials 8.4.13.3. Product landscape 8.4.13.4. Strategic initiatives 8.4.13.5. SWOT analysis 8.4.14. Johnson & Johnson Pvt. Ltd. 8.4.14.1. Company overview 8.4.14.2. Key financials 8.4.14.3. Product landscape 8.4.14.4. Strategic initiatives 8.4.14.5. SWOT analysis 8.4.15. Amgen Inc. 8.4.15.1. Company overview 8.4.15.2. Key financials 8.4.15.3. Product landscape 8.4.15.4. Strategic initiatives 8.4.15.5. SWOT analysis 8.4.16. Teva pharmaceutical Industries Ltd. 8.4.16.1. Company overview 8.4.16.2. Key financials 8.4.16.3. Product landscape 8.4.16.4. Strategic initiatives 8.4.16.5. SWOT analysis 8.4.17. Takeda Pharmaceutical Co. Ltd. 8.4.17.1. Company overview 8.4.17.2. Key financials 8.4.17.3. Product landscape 8.4.17.4. Strategic initiatives 8.4.17.5. SWOT analysis 8.4.18. Astellas Pharma Inc 8.4.18.1. Company overview 8.4.18.2. Key financials 8.4.18.3. Product landscape 8.4.18.4. Strategic initiatives 8.4.18.5. SWOT analysis 8.4.19. Eli Lilly 8.4.19.1. Company overview 8.4.19.2. Key financials 8.4.19.3. Product landscape 8.4.19.4. Strategic initiatives 8.4.19.5. SWOT analysis 8.4.20. F.Hoffmann-La Roche Ltd. 8.4.20.1. Company overview 8.4.20.2. Key financials 8.4.20.3. Product landscape 8.4.20.4. Strategic initiatives 8.4.20.5. SWOT analysis 8.4.21. Joh 8.4.21.1. Company overview 8.4.21.2. Key financials 8.4.21.3. Product landscape 8.4.21.4. Strategic initiatives 8.4.21.5. SWOT analysis 8.4.22. Roche Holding AG 8.4.22.1. Company overview 8.4.22.2. Key financials 8.4.22.3. Product landscape 8.4.22.4. Strategic initiatives 8.4.22.5. SWOT analysis 8.4.23. Novartis AG 8.4.23.1. Company overview 8.4.23.2. Key financials 8.4.23.3. Product landscape 8.4.23.4. Strategic initiatives 8.4.23.5. SWOT analysis 8.4.24. Thermo Fisher Scientific Inc. 8.4.24.1. Company overview 8.4.24.2. Key financials 8.4.24.3. Product landscape 8.4.24.4. Strategic initiatives 8.4.24.5. SWOT analysis 8.4.25. Laboratory Corporation of America Holdings 8.4.25.1. Company overview 8.4.25.2. Key financials 8.4.25.3. Product landscape 8.4.25.4. Strategic initiatives 8.4.25.5. SWOT analysis